Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.
- Completed full-wafer manufacturing runs of 12CQ quantum chip components
- Demonstrated quantum neural network for fraud detection in simulation and hardware
- Advanced Biochip beta prototype with improved cartridge and electronics
- Secured $7 million share placement to fund technology roadmaps
- Entered strategic partnership with IonQ for quantum compute access
Quantum Chip Manufacturing Reaches Wafer Scale
Archer Materials (ASX:AXE) marked a pivotal quarter by completing full-wafer manufacturing runs of its refined 12CQ graphene spin qubit designs, a critical step toward demonstrating a functional qubit. The company is progressing beyond laboratory prototypes, focusing on scalability using existing semiconductor foundry infrastructure. This approach aims to sidestep the commercialisation hurdles faced by quantum technologies requiring new fabrication methods, potentially accelerating Archer’s pathway to market-ready quantum chips.
The wafer-scale fabrication not only advances the quantum computing agenda but also opens avenues in quantum sensing, photonics, and AI infrastructure. Archer’s unified platform could thus tap multiple high-growth technology sectors, broadening its commercial prospects without diluting its core focus on quantum computing.
Quantum Neural Network Shows Promise in Fraud Detection
In collaboration with CSIRO, Archer demonstrated proof-of-concept results for its quantum neural network (QNN) targeting financial fraud detection. Using a dataset of over 280,000 transactions, the QNN identified 118 of 148 fraudulent cases with a single false positive in simulation, outperforming classical machine learning benchmarks. Hardware tests on commercial quantum systems confirmed real-world operability, detecting 18 of 19 fraud instances despite noise challenges.
This early success underscores the potential of quantum machine learning to address the escalating sophistication of financial crime, a global issue costing hundreds of billions annually. Archer’s next steps involve refining the QNN and benchmarking performance to engage potential customers.
Biochip Beta Prototype Advances Toward Clinical Testing
Archer’s Biochip program transitioned from alpha to beta prototype stage, integrating proprietary sensing chips, cartridge design, microfluidics, and electronic readout systems. The beta prototype is designed for external laboratory evaluation and pre-clinical validation, with contract development and manufacturing organisations engaged to support scale-up plans.
Complementing these technical advances, Archer fortified its intellectual property portfolio with new Australian patent grants and provisional filings, reinforcing its competitive moat ahead of commercial partner discussions. The Biochip’s initial focus remains on chronic kidney and cardiovascular disease diagnostics, with potential applications across broader medical and industrial sectors.
Financial Position Strengthened by $7 Million Placement
Post-quarter, Archer completed a well-supported $7 million share placement, bolstering its cash reserves to $8.41 million with no debt. This capital injection underpins ongoing development in quantum computing, quantum machine learning, and advanced materials programs, including the Biochip.
The funding also supports Archer’s strategic Quantum Compute Agreement with IonQ (NYSE: IONQ), granting access to IonQ’s leading quantum cloud infrastructure and enabling accelerated algorithm development and deployment. This partnership is central to Archer’s ambition to establish sovereign quantum computing capability in Australia.
CEO Dr Simon Ruffell highlighted the company’s robust position entering FY27, emphasising consistent progress across all technology pillars and strong institutional investor support across the Asia-Pacific region.
Bottom Line?
Archer’s wafer-scale quantum chip fabrication and promising quantum neural network results, backed by fresh capital and a strategic IonQ partnership, set the stage for a critical development phase in FY27.
Questions in the middle?
- How soon can Archer demonstrate a fully functional qubit ready for commercial foundry manufacturing?
- What are the timelines and milestones for Biochip beta prototype trials and potential market entry?
- How will the IonQ partnership influence Archer’s quantum software development and commercial partnerships?